A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Risvodetinib (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Acronyms 201 trial
- Sponsors Inhibikase Therapeutics
- 21 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Sep 2024.
- 17 Jun 2024 According to an Inhibikase Therapeutics media release, the company has completed enrollment in the Phase 2 201 trial and expects to report trial results in the fourth quarter of 2024.
- 05 Jun 2024 According to an Inhibikase therapeutics media release, the trial has reached 94 percent enrollment and company anticipate enrolling the last patient in mid-June. The Company anticipates that the last patient will complete the 12-week treatment period before the close of the third quarter of 2024. The Company expects to report biomarker and outcome data to support the pursuit of an End of Phase 2 and Phase 3 protocol discussion with the FDA by the end of 2024.